ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2

SARS-CoV-2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwanaga, Naoki, Cooper, Laura, Rong, Lijun, Maness, Nicholas J., Beddingfield, Brandon, Qin, Zhongnan, Crabtree, Jackelyn, Tripp, Ralph A., Yang, Haoran, Blair, Robert, Jangra, Sonia, García-Sastre, Adolfo, Schotsaert, Michael, Chandra, Sruti, Robinson, James E., Srivastava, Akhilesh, Rabito, Felix, Qin, Xuebin, Kolls, Jay K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686446/
https://www.ncbi.nlm.nih.gov/pubmed/34957381
http://dx.doi.org/10.1016/j.isci.2021.103670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686446/
https://www.ncbi.nlm.nih.gov/pubmed/34957381
http://dx.doi.org/10.1016/j.isci.2021.103670

Ejemplares similares